Floatz logo

Ibrutinib

Philadelphia Chromosome Positive

University of California, DavisSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Philadelphia Chromosome Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 3BB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 3BB
Blinatumomab
M.D. Anderson Cancer Center
Phase 2BB

View all 28 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →